📌 A medicinal product may be defined by presentation, by function, or by composition, including certain dietary products containing chemical or biological substances that confer therapeutic-dietetic properties.
Presentation identifies what a product appears to be, whereas function identifies what it does.
★ Must-know
📌 A generic medicine has the same active-ingredient composition as the reference specialty and must demonstrate bioequivalence, whereas a me-too medicine has a modified but similar structure.
Further detail
Reference product → generic → magistral, officinal, hospital preparation
🔄 Drug discovery proceeds through these stages:
Drug targets include:
📌 In vitro experiments are performed outside a living organism, whereas in vivo experiments are performed in a living organism.
Target → design → library → screening → optimization
★ Must-know
Further detail
UniProt is a database of protein or nucleic-acid sequences, whereas the Protein Data Bank is a database of three-dimensional structures.
The seven pharmacophore functions are:
Receptor-based modeling starts from the target, whereas receptor-free modeling starts from molecular structure.
★ Must-know
Further detail
The common international nonproprietary-name suffixes -olol and -azepam group beta-blockers and benzodiazepines, respectively.
To develop a me-too, an industrial company monitors competitors' patents, synthesizes uncovered analogues, selects one using preclinical studies, files a patent, conducts clinical studies, requests marketing authorization, and markets the product.
Acetylsalicylic acid, or aspirin, is obtained by adding acetic acid to the hydroxyl group of salicylic acid through an ester bond.
A generic is identical to the reference product, whereas a me-too is structurally similar but distinct.
★ Must-know
Drug research and development lasts approximately 10 years, costs more than one billion euros overall, and is protected by a patent lasting 20 years.
🔄 Drug development includes:
Further detail
Preclinical development costs approximately 10 to 20 million euros, whereas the early preclinical stage described in the course costs approximately 1.5 million euros and has 90% failures.
After identification of a lead, galenic, pharmacokinetic, pharmacodynamic, and toxicological studies are performed to prepare the medicine and establish patient-safety rules.
Discovery → preclinical → clinical phases → marketing authorization
★ Must-know
Clinical development progresses from phase I to phase IV, with progressively larger numbers of subjects, from fewer than 100 in phase I to several thousand in phase III.
Phase I studies the maximum tolerated dose, pharmacokinetics, and pharmacodynamics when possible in fewer than 100 healthy volunteers.
Phase II evaluates potential efficacy and toxicity, the dose-effect relationship, and the optimal dose in fewer than 500 volunteer patients.
Phase III evaluates the benefit-risk ratio, defines the indication and special populations, and can support marketing authorization in fewer than 5000 ill patients.
Further detail
Phase I tolerability → Phase II dose → Phase III benefit-risk → Phase IV real-world use
★ Must-know
📌 Pharmacokinetics describes what the organism does to the medicine through the dose-concentration relationship, whereas pharmacodynamics describes what the medicine does to the organism through the concentration-effect relationship.
📌 Passive diffusion follows a concentration gradient, uses no energy or transporter, and is not saturable, whereas facilitated diffusion uses saturable transporters and can involve competition between medicines.
Distribution separates the active free fraction from the protein-bound reserve fraction, whose weak reversible binding can compete and is reduced during hypoalbuminemia.
Drug metabolism mainly occurs in the liver and includes phase I functionalization by oxidation, reduction, or hydrolysis followed by phase II conjugation with endogenous polar molecules.
Further detail
ADME: Absorption, Distribution, Metabolism, Elimination.
★ Must-know
Medicine quality requires quality, safety, and efficacy, which are assessed through quantitative and qualitative analytical studies based on physicochemical methods.
The World Health Organization acts internationally, the Council of Europe acts at the European level through the European Pharmacopoeia, and the ANSM applies the framework nationally in France.
📌 Analytical controls qualify what is present, quantify how much is present, identify substances, and detect impurities or related substances that should be absent or below defined limits.
Further detail
Raw materials → formulation → packaging → finished-product control
★ Must-know
Further detail
Galenic forms can be classified by physical appearance as solid, liquid, semisolid, or gaseous, or by administration route as oral, parenteral, or cutaneous.
A syrup is an aqueous preparation with a sweet taste and viscous consistency, containing at least 45% m/m sucrose or another specified polyol or sweetener.
An emulsion disperses liquid globules in another immiscible liquid, with either a lipophilic phase in a hydrophilic phase or a hydrophilic phase in a lipophilic phase.
Gastro-resistant tablets resist gastric juice and release their active substances in intestinal juice.
Oral administration uses the digestive route, whereas parenteral administration crosses the skin.
★ Must-know
📌 Prescribing should follow the marketing authorization and the Summary of Product Characteristics, account for benefit-risk, and use explicit information adapted to the patient's pathology, history, allergies, previous treatments, and expectations.
An ordonnance must include the date, prescriber identification, patient identification, medicine name, form, dose, route, duration, renewal instruction, and the prescriber's signature immediately below the last line.
The four types of ordonnance are:
📌 A hospital-prescription medicine must be prescribed in a health establishment but may be dispensed in the community, whereas a hospital-initial-prescription medicine may be renewed by any prescriber after the initial hospital prescription.
Further detail
Patient → medicine → dose → route → duration → signature
| Phase | Population | Main objective |
|---|---|---|
| I | Fewer than 100 healthy volunteers | Maximum tolerated dose, pharmacokinetics, and possible pharmacodynamics |
| II | Fewer than 500 volunteer patients | Efficacy, toxicity, dose-effect relationship, and optimal dose |
| III | Fewer than 5000 ill patients | Benefit-risk, indication, special populations, and marketing authorization |
| IV | Patients after marketing | Comparison, pharmacoeconomics, tolerance, and usefulness |
| Category | Initial prescriber | Renewal |
|---|---|---|
| PH | Hospital or clinic prescriber | Treatment may be dispensed in the community |
| PIH | Hospital or clinic prescriber | Any prescriber after the initial prescription |
| PRS | Certain specialist physicians | Any physician when only the initial prescription is restricted |
| Exceptional medicine | Qualified prescriber on CERFA form | Subject to the specific prescription requirements |
Teste tes connaissances sur Medicinal Product Knowledge avec 35 questions à choix multiples et corrections détaillées.
1. Which component of a medicinal product is directly responsible for its therapeutic action?
2. What is the primary role of an excipient in a medicinal product?
Mémorisez les concepts clés de Medicinal Product Knowledge avec 74 flashcards interactives.
What is an active ingredient in a medicinal product?
It is the substance responsible for the therapeutic action.
What role does an excipient play in a medicinal product?
It facilitates administration, formulation, and preservation of the active ingredient.
What must an excipient be toward the organism and active ingredient?
It must be inert.
Importe ton cours et l'IA génère fiches, QCM et flashcards en 30 secondes.
Générateur de fiches